TY - JOUR
T1 - Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease
T2 - Current Perspectives
AU - Zulfikar, Sabrina
AU - Mulholland, Sarah
AU - Adamali, Huzaifa
AU - Barratt, Shaney
N1 - © 2020 Zulfikar et al.
PY - 2020/7/13
Y1 - 2020/7/13
N2 - Idiopathic pulmonary fibrosis is a progressive fibrosing interstitial lung disease for which there is no known cure. Currently available therapeutic options have been shown at best to slow the progression of the disease and thus there remains an urgent unmet need to identify new therapies. In this article, we will discuss the mechanisms of action, pre-clinical and clinical trial data surrounding inhibitors of the autotaxin-lysophosphatidic acid axis, which show promise as emerging novel therapies for fibrotic lung disease.
AB - Idiopathic pulmonary fibrosis is a progressive fibrosing interstitial lung disease for which there is no known cure. Currently available therapeutic options have been shown at best to slow the progression of the disease and thus there remains an urgent unmet need to identify new therapies. In this article, we will discuss the mechanisms of action, pre-clinical and clinical trial data surrounding inhibitors of the autotaxin-lysophosphatidic acid axis, which show promise as emerging novel therapies for fibrotic lung disease.
UR - https://research-information.bris.ac.uk/en/publications/10730e06-f0d1-499c-aa39-04236ae19915
U2 - 10.2147/CPAA.S228362
DO - 10.2147/CPAA.S228362
M3 - Article (Academic Journal)
C2 - 32765123
SN - 1179-1438
VL - 12
SP - 97
EP - 108
JO - Clinical pharmacology : advances and applications
JF - Clinical pharmacology : advances and applications
ER -